BioCentury | Mar 28, 2019
Financial News

Antidepressant developer ATAI raises $43M series B round

...Investment Group, which is the family office of ATAI co-founder Christian Angermayer; Bail Capital; and Pura...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Neurology

...the repeats, RNA foci formed and sequestered RNA-binding proteins, including heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1), purine-rich element binding protein A (PURA)...
BioCentury | Nov 7, 2013
Cover Story

ALS antisense oligonucleotides

...foci often colocalized with RNA-binding proteins including heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) and purine-rich element binding protein A ( PURA...
BioCentury | Apr 11, 2013
Distillery Techniques

Technology: Disease models

...expression of the repeat was sufficient to cause degeneration of neuronal cells, and overexpression of purine-rich element binding protein A (PURA)...
...additional studies to validate the toxicity of the GGGGCC repeats and studying the distribution of PURA...
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...published online Jan. 2, 2012; doi:10.1083/jcb.201105013 Contact: Pura Muñoz-Cánoves, Pompeu Fabra University, Barcelona, Spain e-mail: pura.munoz@upf.edu BC...
BioCentury | Feb 2, 2012
Distillery Therapeutics

Indication

...published online Jan. 2, 2012; doi:10.1083/jcb.201105013 Contact: Pura Muñoz-Cánoves, Pompeu Fabra University, Barcelona, Spain e-mail: pura.munoz@upf.edu...
Items per page:
1 - 6 of 6